Kyverna Therapeutics, Inc.
KYTXHealthcare|Biotechnology|US
$4.88
+0.27 (+5.86%)
DCF Value
$2.04
Tangible Book / Share
$2.72
Cash / Share
$3.27
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06193889 KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized Myasthenia Gravis | P2P3 | Recruiting | 66 | RCT, Open-label | Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101 |
| NCT06475495 Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P1P2 | Active | 13 | RCT, Open-label | KYV101, Rituximab (active comparator) |
| NCT06384976 KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | P2 | Active | 120 | RCT, Open-label | KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB |
| NCT06451159 A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis | Progressive Multiple Sclerosis | P1 | Active | 10 | Open-label | KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU) |
| NCT06138132 A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis | Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | P1 | Recruiting | 12 | Open-label | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen |
| NCT06152172 CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | P1 | Active | 24 | Open-label | KYV-101, Cyclophosphamide, Fludarabine |
| NCT07403188 A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | Refractory Lupus Nephritis, Myasthaenia Gravis | Recruiting | 70 | — | KYV-101 | |
| NCT06590545 Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | ANCA-IgG-positive ANCA Associated Vasculitis | P1P2 | Not Yet Recruiting | 8 | Open-label | KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy |
| NCT06588491 KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome | Stiff-Person Syndrome, SPS | P2 | Completed | 27 | Open-label | Standard lymphodepletion regimen |
| NCT06342960 KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Lupus Nephritis, Lupus Nephritis - WHO Class III | P1P2 | Terminated | 2 | Open-label | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen |
| NCT05938725 KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | P1P2 | Terminated | 6 | Open-label | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen |
| NCT06400303 KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis | Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | P1P2 | Terminated | 3 | Open-label | KYV-101, Standard lymphodepletion regimen |